Cargando…

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma

INTRODUCTION: Soluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Sang Eun, Park, Sujin, Cho, Junhun, Ryu, Kyung Ju, Yandava, Booma, Lee, Sewon, Kim, Seok Jin, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687412/
https://www.ncbi.nlm.nih.gov/pubmed/38033491
http://dx.doi.org/10.3389/fonc.2023.1194315
_version_ 1785151972334108672
author Yoon, Sang Eun
Park, Sujin
Cho, Junhun
Ryu, Kyung Ju
Yandava, Booma
Lee, Sewon
Kim, Seok Jin
Kim, Won Seog
author_facet Yoon, Sang Eun
Park, Sujin
Cho, Junhun
Ryu, Kyung Ju
Yandava, Booma
Lee, Sewon
Kim, Seok Jin
Kim, Won Seog
author_sort Yoon, Sang Eun
collection PubMed
description INTRODUCTION: Soluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL). METHODS: We analyzed sMICA/sMICB, cytokine in serum, and macrophage polarization analysis in tissue samples before the first chemotherapy administration. This research was performed to investigate the correlation between sMICA/sMICB expression and treatment outcomes as well as their influence on the immune system within ND-DLBCL. RESULTS: Of the 262 patients, 47.3% (n = 124) presented stage III or IV at diagnosis and 50.8% (n = 133) had a high International Prognostic Index (IPI ≥ 3). The patients with high (p = 0.034 and 0.004), elevated lactate dehydrogenase (p = 0.002 and 0.030), advanced stage (p = 0.003 and 0.012), and higher IPI risk (p = 0.009, and 0.032) correlated with the detection of sMICA or sMICB. The median progression-free survival (PFS) of patients with sMICA (p = 0.006) or sMICB (p =0.032) was inferior. Among the patients with advanced-stage or high IPI, those with sMICA or sMICB presented an inferior PFS and OS compared to those without. TNF-a, a pro-inflammatory cytokine, showed statistical significance with detected sMICA (p = 0.035) or sMICB (p = 0.044). Among anti-inflammatory cytokines, IL-1RA (P-value = 0.013) and IL-10 (p = 0.005) were associated with detecting sMICB, but not sMICA. In tissue samples, sMICA or sMICB detection did not correlate with the CD68/CD163 ratio. DISCUSSION: Conclusively, the identification of sMICA/sMICB presented unfavorable immunochemotherapy outcomes, and it was assumed that sMICA or sMICB and various cytokines interact, but the relationship with macrophage differentiation is unclear. Therefore, further research is needed to determine the relationship between sMICA/sMICB and tumor microenvironment in DLBCL.
format Online
Article
Text
id pubmed-10687412
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106874122023-11-30 The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma Yoon, Sang Eun Park, Sujin Cho, Junhun Ryu, Kyung Ju Yandava, Booma Lee, Sewon Kim, Seok Jin Kim, Won Seog Front Oncol Oncology INTRODUCTION: Soluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL). METHODS: We analyzed sMICA/sMICB, cytokine in serum, and macrophage polarization analysis in tissue samples before the first chemotherapy administration. This research was performed to investigate the correlation between sMICA/sMICB expression and treatment outcomes as well as their influence on the immune system within ND-DLBCL. RESULTS: Of the 262 patients, 47.3% (n = 124) presented stage III or IV at diagnosis and 50.8% (n = 133) had a high International Prognostic Index (IPI ≥ 3). The patients with high (p = 0.034 and 0.004), elevated lactate dehydrogenase (p = 0.002 and 0.030), advanced stage (p = 0.003 and 0.012), and higher IPI risk (p = 0.009, and 0.032) correlated with the detection of sMICA or sMICB. The median progression-free survival (PFS) of patients with sMICA (p = 0.006) or sMICB (p =0.032) was inferior. Among the patients with advanced-stage or high IPI, those with sMICA or sMICB presented an inferior PFS and OS compared to those without. TNF-a, a pro-inflammatory cytokine, showed statistical significance with detected sMICA (p = 0.035) or sMICB (p = 0.044). Among anti-inflammatory cytokines, IL-1RA (P-value = 0.013) and IL-10 (p = 0.005) were associated with detecting sMICB, but not sMICA. In tissue samples, sMICA or sMICB detection did not correlate with the CD68/CD163 ratio. DISCUSSION: Conclusively, the identification of sMICA/sMICB presented unfavorable immunochemotherapy outcomes, and it was assumed that sMICA or sMICB and various cytokines interact, but the relationship with macrophage differentiation is unclear. Therefore, further research is needed to determine the relationship between sMICA/sMICB and tumor microenvironment in DLBCL. Frontiers Media S.A. 2023-11-16 /pmc/articles/PMC10687412/ /pubmed/38033491 http://dx.doi.org/10.3389/fonc.2023.1194315 Text en Copyright © 2023 Yoon, Park, Cho, Ryu, Yandava, Lee, Kim and Kim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yoon, Sang Eun
Park, Sujin
Cho, Junhun
Ryu, Kyung Ju
Yandava, Booma
Lee, Sewon
Kim, Seok Jin
Kim, Won Seog
The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
title The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
title_full The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
title_fullStr The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
title_full_unstemmed The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
title_short The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
title_sort impact of smica/smicb on immunochemotherapy outcomes in newly diagnosed diffuse large b-cell lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687412/
https://www.ncbi.nlm.nih.gov/pubmed/38033491
http://dx.doi.org/10.3389/fonc.2023.1194315
work_keys_str_mv AT yoonsangeun theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT parksujin theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT chojunhun theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT ryukyungju theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT yandavabooma theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT leesewon theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT kimseokjin theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT kimwonseog theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT yoonsangeun impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT parksujin impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT chojunhun impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT ryukyungju impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT yandavabooma impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT leesewon impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT kimseokjin impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma
AT kimwonseog impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma